Beyond excited for Society For Melanoma Research meeting In Salt Lake City. Please don't miss the Women in Science session on Thursday at 2 pm. I will be co-facilitating a group meeting on Negotiations, Hiring and Promotions with @sloan_kettering 's Paul Chapman.

In high school, girls have more credits and better GPA in math and science; but are more likely to leave STEM fields and are under-represented in leadership roles in academia. Allison Betof, MD, PhD @mcquadeMDLAc @RieWeb20 on stage with Dr. Beckerle.

Great talk on #womeninscience & #WomenInSTEM from CEO of Huntsman Cancer Institute. Her tips on professional joy below! Society For Melanoma Research congress.

Fantastic talk by Megan Insco about CDK13 mutations in melanoma. Society For Melanoma Research

Dr. Mike Davies MD Anderson Cancer Center and colleagues present interesting prelim data for OXPHOSi in prevention/treatment of melanoma brain metastases... area of huge unmet need

In case you are wondering about IL-6 inhibitor Tociluzumab effect in #COVID19 serious infections: N=20. 19/20 discharged in 2 weeks. Improvement in lung lesions. Reduction in fever/C-reactive protein, increase O2 saturation among others. LINK to paper chinaxiv.org/abs/202003.000…

#COVID19 Bar Chart from 3/1 to 3/22 worldwide

@drdonsdizon I have blown my cover...it now has to be a stealth mission to capture them. Stay tuned.

Bravo ASCO The ASCO Post for profiling a #mentor #leader #brother Steven Dana-Farber a roadmap to contributing and educating. Dr. Hodi has lead the combination of Immunotherapeutics since his groundbreaking Ipi-avastin trials.

So wonderful to discuss melanoma with such an amazing group of women. AIM at Melanoma Foundation

Head to head comparison of triple therapy trial outcomes in #melanoma from Zeynep Eroglu Moffitt Cancer Center Other relevant mPFS comparators noted by Yana Najjar: -ipi/nivo 16.8m (Checkmate 067) -enco/bini 14.9m (COLUMBUS) #WomenInMelanoma AIM at Melanoma Foundation #WomenInMedicine

Join me on Jan. 27, for the Society for Immunotherapy of Cancer #LearnACI live virtual Intratumoral Therapies, Vaccines and Cytokines program featuring in-depth education on all aspects of clinical implementation of immunotherapy. Register today and invite a colleague: sitcancer.org/education/aci/…

Wonderful tribute to Val Guild who transformed melanoma care, research and delivery by John M. Kirkwood and Thach Giao at the ⁦ECOG-ACRIN Cancer Research Group⁩ and SWOG Cancer Research Network social. ⁦⁦AIM at Melanoma Foundation⁩

Adjuvant pembro in stage IIB/C melanoma from Keynote-716 by Professor Georgina Long AO (Bluesky @gvlongphdmd) with statistically significant DMFS difference at 2 years - 88.1 v 82.2 RFS widened a smidge at 2 yrs Conclusion? stage II adjuvant conversation still a tough one #ASCO22

Forget your sunscreen? Mass General Brigham has got you covered 🧴🧴🧴IMPACT Melanoma

Good morning from Women in Melanoma 🌞 Emily Tonirezos National Cancer Institute kicking off the agenda talking about the definition of cancer survivor, so well worded: An individual is considered a cancer survivor from the time of diagnosis through the balance of life #WIM23 AIM at Melanoma Foundation

Engaged and leaning in for this talk AIM at Melanoma Foundation #WIM meeting on “Disenfranchised grief” by Molly Vocino from Jefferson Health Sidney Kimmel Comprehensive Cancer Center Trajectory of #grief, grief v trauma, over-pathologizing grief

Update in #melanoma #TIL news: lifileucel PDUFA date pushed back to Feb 2024 due to delays on the FDA Oncology end. This isn’t a problem with the data etc. This is a huge hit to patients desperately waiting for this lifesaving treatment. We already have waitlists and now there

SITC thanks Drs. Pavlick & Sullivan and all members of our SITC Melanoma Immunotherapy Guideline Expert Panel for their efforts in developing this clinical practice guideline. elizabeth buchbinder Omid Hamid MD Tina J Hieken MD Keith Tolley #SITCGuidelines #melanoma #skincancer

New #JITC article: Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab bit.ly/3MrU0O4 Tammy Sussman MD Annie Silk Riz Haq MD PhD elizabeth buchbinder